Frier Levitt Named Winston S. Kirton FDA Practice Chair
Winston S. Kirton has been appointed as the new partner and chair of the FDA practice at Frier Levitt.
Updated on Sept. 24, 2026 in People
Frier Levitt announced that Winston S. Kirton has joined the firm as a partner and the new chair of its FDA practice. Kirton transitions into this leadership role following his previous tenure as a co-lead of the FDA and Life Sciences team at BakerHostetler.
Why it matters
The appointment strengthens Frier Levitt's regulatory capabilities by adding a veteran attorney with deep experience in food and drug law. This move helps the firm navigate complex life sciences compliance issues for its clients in the United States.
Winston S. Kirton assumes his role as the leader of the FDA practice after previously serving as a co-lead of the FDA and Life Sciences team at BakerHostetler.
The players
Winston S. Kirton
He is an experienced attorney who previously co-led the FDA and Life Sciences team at BakerHostetler and serves on the Board of Directors for the Food and Drug Law Institute.
Frier Levitt
It is a law firm specializing in healthcare and life sciences law that operates within the United States.
BakerHostetler
It is a national law firm where Winston S. Kirton formerly served as a co-leader of the FDA and Life Sciences practice.
Food and Drug Law Institute
It is a nonprofit organization that provides a neutral forum for discussing food and drug law issues and where Winston S. Kirton serves on the Board of Directors.
The details
Kirton joins the firm with extensive experience in the life sciences sector and continues his service on the Board of Directors for the Food and Drug Law Institute. His arrival at Frier Levitt follows his departure from the law firm BakerHostetler.
Timeline
September 24, 2026: Winston S. Kirton was named as the new partner and chair of the FDA practice.
Market Landscape
The legal industry is currently seeing a shift toward specialized regulatory talent as firms compete to provide high-level compliance expertise in a changing healthcare environment. This move allows Frier Levitt to better position itself against major competitors by centralizing its FDA practice under seasoned leadership.
Clients of Frier Levitt may see changes in how the firm handles complex life sciences compliance and FDA regulatory filings. This appointment suggests a focus on strengthening legal support services for companies operating within the highly regulated healthcare sector.
The takeaway
Leadership changes at specialized law firms often signal a strategic pivot toward deepening expertise in high-demand regulatory areas. Clients looking for counsel in the food and drug space should monitor how new practice chairs align their legal strategies with emerging federal requirements.
Further reading
Explore industry movements and leadership transitions on the People section.
Source note: This article includes information reported by NJBIZ.
